Evidence map›Paper›PMID 28979719›Full record

ArticleWorld journal of gastrointestinal oncology2017

Yuji Kaneda, Hiroshi Noda, Yuhei Endo, Nao Kakizawa, Kosuke Ichida, Fumiaki Watanabe, Takaharu Kato, Yasuyuki Miyakura, Koichi Suzuki, Toshiki Rikiyama

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastrointestinal oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yuji KanedaDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Hiroshi NodaDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan. noda164@omiya.jichi.ac.jp.
Yuhei EndoDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Nao KakizawaDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Kosuke IchidaDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Fumiaki WatanabeDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Takaharu KatoDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Yasuyuki MiyakuraDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Koichi SuzukiDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Toshiki RikiyamaDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330-8503, Japan.
Jichi Medical University · JPJichi Medical University Saitama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the usefulness of

methodsWe retrospectively reviewed the database of Saitama Medical Center, Jichi Medical University, between January 2009 and December 2016. During this time, 299 patients underwent radical right hemicolectomy for right-sided colon cancer. Among them, 5 underwent RHCPD for LARCC with tumor infiltration to adjacent organs. Preoperative computed tomography (CT) was routinely performed to evaluate local tumor infiltration into adjacent organs. During the operation, we evaluated the resectability and the amount of infiltration into the adjacent organs without dissecting the adherent organs from the cancer. When we confirmed that radical resection was feasible and could lead to R0 resection, we performed RHCPD. The clinical data were carefully reviewed, and the demographic variables, intraoperative data, and postoperative parameters were recorded.

resultsThe median age of the 5 patients who underwent RHCPD for LARCC was 70 years. The tumors were located in the ascending colon (three patients) and transverse colon (two patients). Preoperative CT revealed infiltration of the tumor into the duodenum in all patients, the pancreas in four patients, the superior mesenteric vein (SMV) in two patients, and tumor thrombosis in the SMV in one patient. We performed RHCPD plus SMV resection in three patients. Major postoperative complications occurred in 3 patients (60%) as pancreatic fistula (grade B and grade C, according to International Study Group on Pancreatic Fistula Definition) and delayed gastric empty. None of the patients died during their hospital stay. A histological examination confirmed malignant infiltration into the duodenum and/or pancreas in 4 patients (80%), and no patients showed any malignant infiltration into the SMV. Two patients were histologically confirmed to have tumor thrombosis in the SMV. All of the tumors had clear resection margins (R0). The median follow-up time was 77 mo. During this period, two patients with tumor thrombosis died from liver metastasis. The overall survival rates were 80% at 1 year and 60% at 5 years. All patients with node-negative status (

conclusionThis study showed that the long-term survival is possible for patients with LARCC if RHCPD is performed successfully, particularly in those with node-negative status.

Indexed as

Inflammatory adhesionLocally advanced right-sided colon cancerMalignant infiltrationPancreaticoduodenectomyRight hemicolectomy

Identifiers

PMID28979719
PMCPMC5605337
OpenAlexW2754546491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.